HEP is a prospective, observational study whose primary goal is to identify clinical characteristics and bio-markers predictive of disease outcome, progression, and treatment response in participants with newly treated focal epilepsy.  The data to be collected on these participants include high-resolution clinical phenotyping (including co-morbidities) and treatment response, neuroimaging, electrophysiology, genomics and proteomics.  

A major objective of the project is to create an open data repository of clinical information and biologic samples for future studies.

HEP: New onset participants were enrolled and followed for up to 5 years (and a minimum of 3 years) of tracking. This study is now closed for enrollment.

HEP2: Treatment resistant participants (HEP2) were enrolled and followed for 2 years. This study is now closed for enrollment.

HEP3: Is currently enrolling idiopathic generalized epilepsy participants and will have follow up to 2 years. The estimated sample size is 380 participants.